Corvus Pharmaceuticals (CRVS) Change in Accured Expenses (2015 - 2026)

Corvus Pharmaceuticals' Change in Accured Expenses history runs 12 years deep, the most recent figure standing at $499000.0 for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 241.78% year-over-year to $499000.0; the TTM figure through Mar 2026 stood at $3.1 million (up 1657.0% YoY), while the FY2025 annual figure was $2.8 million, up 1226.94% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $499000.0, down from $765000.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $2.2 million in Q3 2022, with the low at -$1.9 million in Q1 2023.
• The 5-year median for Change in Accured Expenses is $101000.0 (2024), against an average of -$5647.1.
• The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses slumped 481.53% in 2022, then soared 895.51% in 2025.
• Corvus Pharmaceuticals' Change in Accured Expenses stood at -$1.0 million in 2022, then jumped by 42.37% to -$589000.0 in 2023, then climbed by 16.81% to -$490000.0 in 2024, then jumped by 256.12% to $765000.0 in 2025, then sank by 34.77% to $499000.0 in 2026.
• Business Quant data shows CRVS's Change in Accured Expenses at $499000.0 in Q1 2026, $765000.0 in Q4 2025, and $708000.0 in Q3 2025.